About Publications

Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.

  • Released: January 01,
    The development of rational therapeutics for infants and children has recently received much attention from the academic community, industry, the U.S. Congress, and the federal government. The members of the Roundtable on Research and Development of Drugs, Biologics, and Medical Devices recognized that a variety of interesting and challenging issues are being raised, from several different perspectives, among a diverse group of interested and affected parties.
  • Released: January 01,
    This book looks at worker safety in the changing workplace and the challenge of ensuring a supply of top-notch occupational safety and health (OSH) professionals. Recommendations are addressed to federal and state agencies, OSH organizations, educational institutions, employers, unions, and other stakeholders.
  • Released: January 01,
    This book, based on the 1999 IOM report Marijuana and Medicine: Assessing the Science Base, is a lay version which is faithful to the original report, but also has an additional chapter on marijuana and the law.
  • Released: January 01,
    The committee's report, Bridging Disciplines in the Brain, Behavioral, and Clinical Sciences, contains recommendations that delineate, enhance, and accelerate a process that is already reflected in many training and research programs.
  • Released: January 01,
    The Forum members felt that scrutiny of that impact on infectious disease prevention, monitoring, and treatment could be highly significant: At its March 1998 workshop, Forum members brought key representatives of the "managed care subsector" to the table to address the large range of pertinent issues.
  • Released: December 01, 1999
    Chemical and Biological Terrorism identifies the R&D efforts needed to implement recommendations in key areas: pre-incident intelligence, detection and identification of chemical and biological agents, protective clothing and equipment, early recognition that a population has been covertly exposed to a pathogen, mass casualty decontamination and triage, use of vaccines and pharmaceuticals, and the psychological effects of terror. Specific objectives for computer software development are also identified.
  • Released: September 01, 1999
    In 1997, after more than a decade of research, the National Cancer Institute (NCI) released a report which provided their assessment of radiation exposures that Americans may have received from radioactive iodine released from the atomic bomb tests conducted in Nevada during the 1950s and early 1960s. This book provides an evaluation of the soundness of the methodology used by the NCI study to estimate: Past radiation doses; Possible health consequences of exposure to iodine-131; Implications for clinical practice; Possible public health strategies--such as systematic screening for thyroid cancer--to respond to the exposures.
  • Released: June 01, 1999
    In an effort to increase knowledge and understanding of the process of assuring data quality and validity in clinical trials, the IOM hosted a workshop to open a dialogue on the process to identify and discuss issues of mutual concern among industry, regulators, payers, and consumers. The presenters and panelists together developed strategies that could be used to address the issues that were identified.
  • Released: April 01, 1999
    We all want to believe that when people get cancer, they will receive medical care of the highest quality. Even as new scientific breakthroughs are announced, though, many cancer patients may be getting the wrong care, too little care, or too much care, in the form of unnecessary procedures. Ensuring Quality Cancer Care provides a comprehensive picture of how cancer care is delivered in our nation, from early detection to end-of-life issues.
  • Released: March 01, 1999
    This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades.